| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/13/2004 | WO2004039957A2 Inhibition of gene expression using rna interfering agents |
| 05/13/2004 | WO2004039951A2 Il-1 receptor based antagonists and methods of making and using |
| 05/13/2004 | WO2004039948A2 Actriib fusion polypeptides and uses therefor |
| 05/13/2004 | WO2004039940A2 Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof |
| 05/13/2004 | WO2004039841A2 Trimeric binding proteins for trimeric cytokines |
| 05/13/2004 | WO2004039838A1 Crystals of insulin analogues and method for the production thereof |
| 05/13/2004 | WO2004039834A2 Recombinant protein variants |
| 05/13/2004 | WO2004039833A1 Composition for the treatment of infection by flaviviridae viruses |
| 05/13/2004 | WO2004039832A2 Leptin-related peptides |
| 05/13/2004 | WO2004039830A2 Bioactivation of particles |
| 05/13/2004 | WO2004039829A2 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| 05/13/2004 | WO2004039430A2 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x |
| 05/13/2004 | WO2004039409A2 Composition comprising activators of ik potassium channels and calcineurin antagonists and use thereof |
| 05/13/2004 | WO2004039403A1 Remedy for corneal failure |
| 05/13/2004 | WO2004039397A1 Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1-antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds |
| 05/13/2004 | WO2004039396A1 Drug containing angiotensin convertase |
| 05/13/2004 | WO2004039395A1 Immunnoevasive agent for preventing graft rejection |
| 05/13/2004 | WO2004039394A1 Novel composition and methods for the treatment of immune related diseases |
| 05/13/2004 | WO2004039393A1 Anti-tumor combinations comprising proteins and chemotherapeutics |
| 05/13/2004 | WO2004039391A1 Viral serpin regulation of inflamation |
| 05/13/2004 | WO2004039334A2 CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING |
| 05/13/2004 | WO2004039333A2 ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME |
| 05/13/2004 | WO2004039329A2 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 05/13/2004 | WO2004039324A2 Anti-hiv (sl9) compounds |
| 05/13/2004 | WO2004039315A2 Method for treating wounds to promote healing |
| 05/13/2004 | WO2004039313A2 Preventing desensitization of receptors |
| 05/13/2004 | WO2004039309A2 Dc-sign isoforms, related compositions and methods for their use in disease therapy |
| 05/13/2004 | WO2004039244A2 Methods and kits for diagnosing tumorigenicity |
| 05/13/2004 | WO2004033495A3 Regulation of human pde6b |
| 05/13/2004 | WO2004019036A3 Method for identifying substances |
| 05/13/2004 | WO2004014302A3 Mechanisms of myoblast transfer in treating heart failure |
| 05/13/2004 | WO2004006990A3 Medical device and method for tissue removal and repair |
| 05/13/2004 | WO2004000415A3 Tissue reconstruction and regeneration |
| 05/13/2004 | WO2003105778A3 Phosphatidylinositol-4-phosphate 5-kinase, type ii beta inhibitors for inhibiting angiogenesis |
| 05/13/2004 | WO2003089472A3 Anti-nls scfv and peptides and uses thereof in nuclear import inhibition |
| 05/13/2004 | WO2003077831A3 Compositions and methods for treating mdma-induced toxicity |
| 05/13/2004 | WO2003070190A3 Surrogate antibodies and methods of preparation and use thereof |
| 05/13/2004 | WO2003066859A3 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 05/13/2004 | WO2003064651A3 Regulation of human membrane-type serine protease |
| 05/13/2004 | WO2003050256A3 Novel human g-protein coupled receptor, hgprbmy34, and variants and methods of use thereof |
| 05/13/2004 | WO2003050245A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 05/13/2004 | WO2003049762A3 Immunisation against chlamydia trachomatis |
| 05/13/2004 | WO2003045420A3 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization |
| 05/13/2004 | WO2003039475A8 Methods of identifying and using modulators of fractalkine receptor |
| 05/13/2004 | WO2003038051A9 Method of inducing apoptosis in hyperproliferative cells |
| 05/13/2004 | WO2003034903B1 Psma antibodies and protein multimers |
| 05/13/2004 | WO2003033657A3 Antisense antiviral agent and method for treating ssrna viral infection |
| 05/13/2004 | WO2003029471A8 Muteins of apolipoprotein d |
| 05/13/2004 | WO2003020208A3 Treatment of neurologic hemorrhage |
| 05/13/2004 | WO2003018595A3 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 05/13/2004 | WO2003006652A3 Inhibition of specific histone deacetylase isoforms |
| 05/13/2004 | WO2002096195A8 Treatment or replacement therapy using transgenic stem cells delivered to the gut |
| 05/13/2004 | WO2002089731A9 Agents for treatment of hcv and methods of use |
| 05/13/2004 | WO2002085447A8 Microprojection array having a beneficial agent containing coating |
| 05/13/2004 | WO2002062836A9 Detection of antibacterial activity in excretory secretory product of adult trichuris suis |
| 05/13/2004 | WO2002056903A9 Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| 05/13/2004 | WO2002038171A9 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/13/2004 | WO2002034272A3 Methods of improving central nervous system functioning |
| 05/13/2004 | WO1992004464A3 Monoclonal antibodies against tenascin |
| 05/13/2004 | US20040093644 Recombinant subunit proteins from porcine parvovirus produced in plants |
| 05/13/2004 | US20040093643 Preparing transgenic plants for use as bioreactors in generation of therapeutic proteins; pharmacogenetics |
| 05/13/2004 | US20040093626 Screening modulators of g-protein couple receptors to identify appetite control agent for treatment of physiological eating disorders and obesity |
| 05/13/2004 | US20040093622 Preparing transgenic rodent expressing genetically engineered immunoglobulins for treatment hypercholesterolemia, atherosclerosis, cystic fibrosis and muscular dystrophy |
| 05/13/2004 | US20040092748 Carbocyclic esters such as 5-chloro-2-methanesulfonylindan-1--yl-4-chlorobenzoate, used as anorexigenic agents; dietetics |
| 05/13/2004 | US20040092736 Collections of compounds |
| 05/13/2004 | US20040092730 Hepatitis C virus non-structural NS3/4A fusion gene |
| 05/13/2004 | US20040092724 Transmembrane mucopolysaccharide for treatment and diagnosis of cell proliferative disorders and cancer; antitumor agents |
| 05/13/2004 | US20040092722 Preparing immunoglobulin for diagnosis and treatment of cardiovascular disorders |
| 05/13/2004 | US20040092721 Ligand comprising monoclonal antibody for treatment of tumors and prevention of tumor metastasis; antitumor agents |
| 05/13/2004 | US20040092720 Prevent binding to immunoglobulins; genetic engineering; leukemia, antiproliferative agents, rheumatic diseases |
| 05/13/2004 | US20040092717 Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| 05/13/2004 | US20040092715 Intracellular signaling molecules |
| 05/13/2004 | US20040092714 Comprises osteoclast associated receptors (OSCAR) for the identifying modulators for treatment of bone disorders |
| 05/13/2004 | US20040092711 Hybrid expression of neisserial proteins |
| 05/13/2004 | US20040092709 Peptide mimics of the cytokine receptor common gamma chain and methods and compositions for making and using the same |
| 05/13/2004 | US20040092590 Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid |
| 05/13/2004 | US20040092582 Antiinflammatory agents; respiratory system disorders; antiarthritic agents; autoimmune diseases; antidiabetic agents |
| 05/13/2004 | US20040092542 Tamper-resistant oral opioid agonist formulations |
| 05/13/2004 | US20040092507 Melanocortin receptor agonists |
| 05/13/2004 | US20040092488 Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity |
| 05/13/2004 | US20040092486 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 05/13/2004 | US20040092474 Controlling cell proliferation; contacting cell with reporter molecules; measuring, calibrating activation |
| 05/13/2004 | US20040092472 Nucleic acid compositions for stimulating immune responses |
| 05/13/2004 | US20040092466 A nucleotide of 8-80 nucleobases specifically hybridizes with the nucleic acid which encodes an aggrecanase to inhibit its expression; Alzheimer's Disease; kits; diagnosis/medical; screening tests |
| 05/13/2004 | US20040092465 Modulation of huntingtin interacting protein 1 expression |
| 05/13/2004 | US20040092464 Antisense agents for gene expression inhibition; primers for diagnosis; drug screening; treating diseases or disorders related to dysregulation of cellular apoptosis |
| 05/13/2004 | US20040092463 PIM-1 is a protein serine/threonine kinase predominantly expressed in hematopoietic tissues; antisense agents for PIM-1 inhibition; treating hyperproliferative diseases; kits; drug screening; diagnostic primers |
| 05/13/2004 | US20040092462 Receptors for lysophosphatidic acid (LPA), aka endothelial differentiation genes (EDG); gene expression inhibition of EDG via antisense agents; drug screening; diagnostic probes; hyperproliferative disorders |
| 05/13/2004 | US20040092461 Modulation of phosphodiesterase 1B expression |
| 05/13/2004 | US20040092451 Adding a fibrinogen-precipitating agent to platelet rich plasma and centrifuging |
| 05/13/2004 | US20040092450 Polypeptide that has mitogenic activity; treating fibroproliferative disorders |
| 05/13/2004 | US20040092449 Administering a luminal cholecystokinin releasing factor polypeptide; treating obesity |
| 05/13/2004 | US20040092448 Adding to multipotent neural stem cells; treating neurodegenerative disorders and brain injuries |
| 05/13/2004 | US20040092447 Uses of kappa-conotoxin PVIIA |
| 05/13/2004 | US20040092445 Increasing hematopoietic progenitor cells in a mammal by adminstering an interleukin-like polypeptide |
| 05/13/2004 | US20040092444 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 05/13/2004 | US20040092443 Long-acting exendins and exendin agonists |
| 05/13/2004 | US20040092442 Inactivation resistant factor VIII |
| 05/13/2004 | US20040092440 Binding immunophilins to tissue; promoters of cell proliferation; moderators of gene expression |
| 05/13/2004 | US20040092439 Migraine and vasodilation treatment |